{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:56:08Z","timestamp":1773284168643,"version":"3.50.1"},"reference-count":87,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["754354"],"award-info":[{"award-number":["754354"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00c3\u00b6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Retinoblastoma (RB) management often involves the combination of chemotherapeutic agents (e.g., carboplatin and etoposide) and techniques (e.g., chemotherapy and thermotherapy). Chemoresistance and relapse, as well as systemic and ocular toxicities of current retinoblastoma chemotherapeutics necessitate the implementation of alternative drugs. Fewer resources and concern for pediatric cancer hinder drug discovery and development in an effective way. To overcome the obstacle, a drug repurposing strategy without intuition was adopted to identify promising drug candidates that are both cytotoxic and selective towards human RB Y79 cells\n                    <jats:italic>in vitro<\/jats:italic>\n                    and an orthotopic xenograft mice model\n                    <jats:italic>in vivo<\/jats:italic>\n                    . By using high-throughput screening, gemcitabine demonstrated high cytotoxicity in Y79 cells, also potentially synergizing with thermotherapy, with minimal impact on a human retinal pigment epithelial RPE-1 cells. Furthermore, the synergistic effect of gemcitabine with carboplatin is superior to the clinically used combination of etoposide with carboplatin. Efficacy studies in orthotopic xenografts showed significant eye survival advantages after intravitreal gemcitabine administration or the combination of intravitreal gemcitabine with systemic carboplatin compared to relevant controls. Importantly, the combination resulted in lower tumor invasion in the optic nerves of the xenografts. Since gemcitabine is an FDA-approved chemotherapeutic agent, already used to treat other pediatric cancers, it could be repurposed to RB treatment alone or in combination with carboplatin, and potentially combined with thermotherapy, providing the basis for an alternative and improved treatment option for RB patients.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0339334","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:41:27Z","timestamp":1772044887000},"page":"e0339334","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-throughput screening of drug libraries identifies a new synergistic drug combination for the treatment of retinoblastoma"],"prefix":"10.1371","volume":"21","author":[{"given":"Po-Jen","family":"Tseng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9172-835X","authenticated-orcid":true,"given":"Irina L.","family":"Sinenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Chambon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damiano","family":"Banfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Zugbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Bel\u00e9n","family":"Cancela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kseniya A.","family":"Glinkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Turcatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Schaiquevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis L.","family":"Munier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Dyson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"1","key":"pone.0339334.ref001","doi-asserted-by":"crossref","first-page":"15021","DOI":"10.1038\/nrdp.2015.21","article-title":"Retinoblastoma","volume":"1","author":"H Dimaras","year":"2015","journal-title":"Nat Rev Dis Primer"},{"issue":"11","key":"pone.0339334.ref002","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/bjo.2009.168062","article-title":"Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators","volume":"94","author":"S Canturk","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"pone.0339334.ref003","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4103\/0971-5851.99731","article-title":"Current therapy and recent advances in the management of retinoblastoma","volume":"33","author":"R Meel","year":"2012","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"7522","key":"pone.0339334.ref004","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nature13813","article-title":"Rb suppresses human cone-precursor-derived retinoblastoma tumours","volume":"514","author":"XL Xu","year":"2014","journal-title":"Nature"},{"issue":"6089","key":"pone.0339334.ref005","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/323643a0","article-title":"A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma","volume":"323","author":"SH Friend","year":"1986","journal-title":"Nature"},{"issue":"10","key":"pone.0339334.ref006","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/hmg\/ddn024","article-title":"Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma","volume":"17","author":"H Dimaras","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"11","key":"pone.0339334.ref007","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.4103\/ijo.IJO_721_20","article-title":"Modern treatment of retinoblastoma: A 2020 review","volume":"68","author":"D Ancona-Lezama","year":"2020","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"pone.0339334.ref008","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/107327481602300203","article-title":"Therapeutic Options for Retinoblastoma","volume":"23","author":"PR Mendoza","year":"2016","journal-title":"Cancer Control"},{"issue":"101","key":"pone.0339334.ref009","first-page":"11","article-title":"Classification and staging of retinoblastoma","volume":"31","author":"ID Fabian","year":"2018","journal-title":"Community Eye Health"},{"issue":"3","key":"pone.0339334.ref010","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/0002-9394(89)90116-5","article-title":"The role of cryotherapy in the management of retinoblastoma","volume":"108","author":"JA Shields","year":"1989","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"pone.0339334.ref011","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1001\/archopht.1996.01100140548005","article-title":"Chemotherapy plus local treatment in the management of intraocular retinoblastoma","volume":"114","author":"AL Murphree","year":"1996","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"pone.0339334.ref012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ohc.2004.11.002","article-title":"Chemotherapy for retinoblastoma","volume":"18","author":"HSL Chan","year":"2005","journal-title":"Ophthalmol Clin North Am"},{"issue":"1","key":"pone.0339334.ref013","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0192623307310955","article-title":"Safety evaluation of ocular drug delivery formulations: techniques and practical considerations","volume":"36","author":"BG Short","year":"2008","journal-title":"Toxicol Pathol"},{"issue":"5","key":"pone.0339334.ref014","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ajo.2014.07.025","article-title":"Retinoblastoma. Fifty years of progress. The LXXI Edward Jackson Memorial Lecture","volume":"158","author":"HE Grossniklaus","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"pone.0339334.ref015","doi-asserted-by":"crossref","first-page":"100764","DOI":"10.1016\/j.preteyeres.2019.05.005","article-title":"Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. \u201cAlive, with good vision and no comorbidity\u201d","volume":"73","author":"FL Munier","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"pone.0339334.ref016","doi-asserted-by":"crossref","unstructured":"Lumbroso L, Doz F, Urbieta M, Levy C, Bours D, Asselain B. Chemothermotherapy in the management of retinoblastoma. 2002;109(6):7.","DOI":"10.1016\/S0161-6420(02)01053-9"},{"issue":"4","key":"pone.0339334.ref017","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/cancers13040669","article-title":"Drug combination in cancer treatment\u2014From cocktails to conjugated combinations","volume":"13","author":"Y Gilad","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"pone.0339334.ref018","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/IIO.0b013e3182010f29","article-title":"Current update on retinoblastoma","volume":"51","author":"SK Houston","year":"2011","journal-title":"Int Ophthalmol Clin"},{"issue":"7","key":"pone.0339334.ref019","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","article-title":"Drug combination therapy increases successful drug repositioning","volume":"21","author":"W Sun","year":"2016","journal-title":"Drug Discov Today"},{"issue":"3","key":"pone.0339334.ref020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059156","article-title":"A synergetic screening approach with companion effector for combination therapy: application to retinoblastoma","volume":"8","author":"JP Mahida","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"pone.0339334.ref021","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays","volume":"4","author":"J Zhang","year":"1999","journal-title":"J Biomol Screen"},{"issue":"7","key":"pone.0339334.ref022","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1039\/D4MD00211C","article-title":"New melphalan derivatives for the treatment of retinoblastoma in combination with thermotherapy","volume":"15","author":"S Zebret","year":"2024","journal-title":"RSC Med Chem"},{"issue":"5","key":"pone.0339334.ref023","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20051077","article-title":"Tridimensional retinoblastoma cultures as vitreous seeds models for live-cell imaging of chemotherapy penetration","volume":"20","author":"U Winter","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"pone.0339334.ref024","doi-asserted-by":"crossref","first-page":"729","DOI":"10.14348\/molcells.2022.2014","article-title":"Establishment and characterization of carboplatin-resistant retinoblastoma cell lines","volume":"45","author":"CS Cho","year":"2022","journal-title":"Molecular Cells"},{"issue":"2","key":"pone.0339334.ref025","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1167\/iovs.07-0653","article-title":"Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma","volume":"49","author":"JY Tsui","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"pone.0339334.ref026","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model","volume":"13","author":"B Yadav","year":"2015","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"pone.0339334.ref027","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1128\/br.20.4.243-258.1956","article-title":"The calculation of microbial assays","volume":"20","author":"CI BLISS","year":"1956","journal-title":"Bacteriol Rev"},{"issue":"9","key":"pone.0339334.ref028","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nchembio817","article-title":"Systems biology and combination therapy in the quest for clinical efficacy","volume":"2","author":"JB Fitzgerald","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"7","key":"pone.0339334.ref029","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"J Schindelin","year":"2012","journal-title":"Nat Methods"},{"issue":"9","key":"pone.0339334.ref030","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.3390\/cancers12092714","article-title":"Clinical, genomic, and pharmacological study of MYCN-Amplified RB1 Wild-Type Metastatic Retinoblastoma","volume":"12","author":"S Zugbi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0339334.ref031","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2016.06.012","article-title":"Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination","volume":"380","author":"G Pascual-Pasto","year":"2016","journal-title":"Cancer Lett"},{"issue":"11","key":"pone.0339334.ref032","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/bjophthalmol-2018-312263","article-title":"Minimal disseminated disease evaluation and outcome in trilateral retinoblastoma","volume":"102","author":"AV Torbidoni","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"pone.0339334.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216744","article-title":"Cell line-specific efficacy of thermoradiotherapy in human and canine cancer cells in vitro","volume":"14","author":"KJ Nytko","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"pone.0339334.ref034","doi-asserted-by":"crossref","first-page":"10724","DOI":"10.1038\/s41598-018-29018-0","article-title":"Hyperthermia induces therapeutic effectiveness and potentiates adjuvant therapy with non-targeted and targeted drugs in an in vitro model of human malignant melanoma","volume":"8","author":"T Mantso","year":"2018","journal-title":"Sci Rep"},{"key":"pone.0339334.ref035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jconrel.2018.04.029","article-title":"Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer","volume":"282","author":"M Dunne","year":"2018","journal-title":"J Controlled Release"},{"issue":"8","key":"pone.0339334.ref036","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.3390\/cells9081775","article-title":"The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines","volume":"9","author":"RFCPA Helderman","year":"2020","journal-title":"Cells"},{"key":"pone.0339334.ref037","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nantod.2017.08.001","article-title":"Thermosensitive nanomedicines could revolutionize thermal therapy in oncology","volume":"16","author":"M Dunne","year":"2017","journal-title":"Nano Today"},{"issue":"2","key":"pone.0339334.ref038","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/eye.2012.175","article-title":"Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy","volume":"27","author":"CL Shields","year":"2013","journal-title":"Eye (Lond)"},{"key":"pone.0339334.ref039","article-title":"Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (Review)","author":"T Boulikas","year":"2004","journal-title":"Oncol Rep"},{"issue":"1","key":"pone.0339334.ref040","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/stem.140018","article-title":"The importance of drug scheduling in cancer chemotherapy: etoposide as an example","volume":"14","author":"KR Hande","year":"1996","journal-title":"Stem Cells"},{"issue":"3","key":"pone.0339334.ref041","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/sj.bjc.6600060","article-title":"Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin","volume":"86","author":"EL Meczes","year":"2002","journal-title":"Br J Cancer"},{"issue":"4","key":"pone.0339334.ref042","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0002-9440(10)64653-6","article-title":"Metastatic and nonmetastatic models of retinoblastoma","volume":"157","author":"P Chevez-Barrios","year":"2000","journal-title":"Am J Pathol"},{"issue":"15","key":"pone.0339334.ref043","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/iovs.64.15.27","article-title":"Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments","volume":"64","author":"S Zugbi","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"pone.0339334.ref044","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jamaophthalmol.2020.0427","article-title":"Genomic and Transcriptomic Tumor Heterogeneity in Bilateral Retinoblastoma","volume":"138","author":"U Winter","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"pone.0339334.ref045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41698-021-00212-0","article-title":"Inter-eye genomic heterogeneity in bilateral retinoblastoma via aqueous humor liquid biopsy","volume":"5","author":"EY Wong","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"pone.0339334.ref046","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"L Galluzzi","year":"2018","journal-title":"Cell Death Differ"},{"issue":"3","key":"pone.0339334.ref047","first-page":"447","article-title":"Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer","volume":"54","author":"S Noble","year":"1997","journal-title":"Drugs"},{"issue":"4","key":"pone.0339334.ref048","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3904\/kjim.2002.17.4.259","article-title":"Gemcitabine therapy in patients with advanced pancreatic cancer","volume":"17","author":"YJ Min","year":"2002","journal-title":"Korean J Intern Med"},{"issue":"18","key":"pone.0339334.ref049","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1517\/14656566.8.18.3251","article-title":"Gemcitabine in bladder cancer","volume":"8","author":"F El Karak","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"pone.0339334.ref050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-007-9610-z","article-title":"Gemcitabine in the management of metastatic breast cancer: a systematic review","volume":"108","author":"S Dent","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"pone.0339334.ref051","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30214","article-title":"Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy","volume":"70","author":"JD Bender","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"pone.0339334.ref052","article-title":"Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin\u2019s lymphoma","author":"A Mahdy","year":"2023","journal-title":"Front Oncol"},{"issue":"9","key":"pone.0339334.ref053","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27246","article-title":"Gemcitabine\/nab-paclitaxel for pediatric relapsed\/refractory sarcomas","volume":"65","author":"JL Metts","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"pone.0339334.ref054","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/JHC.S94008","article-title":"Pediatric hepatocellular carcinoma: challenges and solutions","volume":"4","author":"I Schmid","year":"2017","journal-title":"J Hepatocell Carcinoma"},{"issue":"2","key":"pone.0339334.ref055","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nrd2683","article-title":"Mechanisms of drug combinations: interaction and network perspectives","volume":"8","author":"J Jia","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"205","key":"pone.0339334.ref056","article-title":"High-throughput methods for combinatorial drug discovery","volume":"5","author":"X Sun","year":"2013","journal-title":"Sci Transl Med"},{"issue":"4","key":"pone.0339334.ref057","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2008.17.1405","article-title":"Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non\u2013small-cell lung cancer","volume":"27","author":"PM Fidias","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"pone.0339334.ref058","first-page":"3069","article-title":"Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma","volume":"29","author":"A Bakshandeh-Bath","year":"2009","journal-title":"Anticancer Res"},{"issue":"2","key":"pone.0339334.ref059","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1310\/hpj5002-103","article-title":"Gemcitabine and Carboplatin (renally dosed) regimen for bladder cancer","volume":"50","author":"E Ryan Pritchard","year":"2015","journal-title":"Hosp Pharm"},{"issue":"34","key":"pone.0339334.ref060","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1200\/JCO.2014.55.2984","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"J O\u2019Shaughnessy","year":"2014","journal-title":"J Clin Oncol"},{"key":"pone.0339334.ref061","article-title":"Gemcitabine and carboplatin regimens in advanced non-small-cell lung cancer: focus on randomized phase III trials","author":"MJ Edelman","year":"2003","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"pone.0339334.ref062","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003495-198223050-00001","article-title":"Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections","volume":"23","author":"AA Carmine","year":"1982","journal-title":"Drugs"},{"issue":"14","key":"pone.0339334.ref063","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-016-0633-9","article-title":"Trifluridine\/Tipiracil: A Review in Metastatic Colorectal Cancer","volume":"76","author":"CB Burness","year":"2016","journal-title":"Drugs"},{"issue":"16","key":"pone.0339334.ref064","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2217\/fon-2018-0147","article-title":"Trifluridine\/tipiracil: an emerging strategy for the management of gastrointestinal cancers","volume":"14","author":"M Peeters","year":"2018","journal-title":"Future Oncol"},{"issue":"14","key":"pone.0339334.ref065","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s40265-019-01195-w","article-title":"Trifluridine\/Tipiracil: A Review in Metastatic Gastric Cancer","volume":"79","author":"C Kang","year":"2019","journal-title":"Drugs"},{"key":"pone.0339334.ref066","author":"JL Nitiss","year":"2012","journal-title":"Curr Protoc Pharmacol"},{"issue":"1","key":"pone.0339334.ref067","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jcph.1275","article-title":"Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients","volume":"59","author":"X Bao","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"pone.0339334.ref068","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2001.19.5.1501","article-title":"Irinotecan in the treatment of colorectal cancer: clinical overview","volume":"19","author":"U Vanhoefer","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0339334.ref069","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s12032-010-9453-z","article-title":"Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer","volume":"28","author":"YS Kim","year":"2011","journal-title":"Med Oncol"},{"issue":"7","key":"pone.0339334.ref070","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40265-017-0741-1","article-title":"Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma","volume":"77","author":"YN Lamb","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"pone.0339334.ref071","first-page":"235","article-title":"Experimental animal study of docetaxel combined with carboplatin in the treatment of retinoblastoma","volume":"16","author":"C Song","year":"2018","journal-title":"Oncol Lett"},{"issue":"10","key":"pone.0339334.ref072","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1001\/archopht.122.10.1510","article-title":"Histological effect and protein expression in subthreshold transpupillary thermotherapy in rabbit eyes","volume":"122","author":"Y Morimura","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"pone.0339334.ref073","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1167\/iovs.04-0436","article-title":"Retinal temperature increase during transpupillary thermotherapy: effects of pigmentation, subretinal blood, and choroidal blood flow","volume":"45","author":"MS Ibarra","year":"2004","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"pone.0339334.ref074","first-page":"109","article-title":"The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas","volume":"27","author":"SJ Rogers","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"pone.0339334.ref075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2022.12.009","article-title":"Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial","volume":"181","author":"RD Issels","year":"2023","journal-title":"Eur J Cancer"},{"issue":"8","key":"pone.0339334.ref076","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bjophthalmol-2011-301450","article-title":"Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: From prohibition to conditional indications","volume":"96","author":"FL Munier","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"13","key":"pone.0339334.ref077","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.3390\/jcm11133642","article-title":"Axial Growth Driven by Physical Development and Myopia among Children: A Two Year Cohort Study","volume":"11","author":"S Chen","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"pone.0339334.ref078","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40123-023-00838-2","article-title":"VIVEX: A Formula for Calculating Individual Vitreous Volume: a new approach towards tailored patient dosing regime in intravitreal therapy","volume":"13","author":"AF Borkenstein","year":"2024","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"pone.0339334.ref079","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27469","article-title":"Salvage regimens for pediatric patients with relapsed nasopharyngeal carcinoma","volume":"66","author":"C DeRenzo","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"pone.0339334.ref080","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MPH.0b013e31820994ec","article-title":"Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children","volume":"33","author":"C Hartmann","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"pone.0339334.ref081","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10147-001-8028-6","article-title":"Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial","volume":"6","author":"D Tassinari","year":"2001","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"pone.0339334.ref082","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1002\/cncr.10990","article-title":"Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy","volume":"97","author":"M Nogu\u00e9-Aliguer","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"pone.0339334.ref083","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3816\/CBC.2004.n.015","article-title":"Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer","volume":"5","author":"FL Nasr","year":"2004","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"pone.0339334.ref084","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cncr.21604","article-title":"The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group","volume":"106","author":"A Bamias","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"pone.0339334.ref085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146582","article-title":"Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma","volume":"11","author":"DH Abramson","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"pone.0339334.ref086","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26394","article-title":"Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children\u2019s Oncology Group","volume":"64","author":"DL Friedman","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"pone.0339334.ref087","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s12885-018-4406-6","article-title":"Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis","volume":"18","author":"Q Chen","year":"2018","journal-title":"BMC Cancer"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:41:45Z","timestamp":1772044905000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0339334"}},"subtitle":[],"editor":[{"given":"Irina V.","family":"Lebedeva","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":87,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0339334","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]}}}